- Category: HBV Treatment
- Published on Monday, 22 April 2013 00:00
- Written by Liz Highleyman
The 48th Annual Meeting of the European Association for the Study of the Liver (EASL 2013) kicks off this Wednesday, April 24, at the Amsterdam RAI congress center. HIVandHepatitis.com will be on site to provide breaking news and analysis starting later this week.
EASL's International Liver Congress is one of the key annual scientific meetings covering hepatitis B and C and its complications, bringing together leading researchers from around the world.
The rapidly evolving hepatitis C drug development pipeline -- with an emphasis on all-oral, interferon-free combination regimens -- will be a major focus this year, several pharmaceutical companies have already announced that they will be presenting new data. Experts expect that the first of the next-generation direct-acting antivirals may be approved for easier-to-treat patients in the U.S. and Europe as early as late 2013-early 2014.
Look for HIVandHepatitis.com's ongoing coverage including web content and tweets from @HIVandHepatitis, starting April 25. Visit the conference web site at http://www2.kenes.com/liver-congress/pages/home.aspx for abstracts and other content.
EASL. International Liver Congress. http://www2.kenes.com/liver-congress/pages/home.aspx.